A new way to sort rare spinal cord tumors
Original title: DNA methylation-based classification and molecular characteristics of spinal cord gliomas with wildtype histone H3 reveal differences between adult and pediatric pilocytic astrocytoma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
Researchers looked at tumor samples from patients to sort them better, not to test a treatment.
The short version
Reading a tumor's DNA pattern helped doctors sort rare spinal cord tumors more exactly.
What was studied. Researchers studied spinal cord tumors from 55 patients. They looked at the DNA, the proteins, and single cells in each tumor. They then checked their method on 31 more cases.
What they found. The DNA pattern split the tumors into six groups. In 58.2% of the cases, these groups did not match the older way of sorting tumors under a microscope. One group, called pilocytic astrocytoma, split again into a child form and an adult form. The adult form had smaller tumors and took longer to grow back, and all of those patients were alive.
What this means, and what it doesn't
What it could mean: A tumor's DNA pattern may give a clearer name than a microscope alone. A clearer name can help your team know what to expect. Over time it may also help point to the right treatment.
What it doesn't mean: This is not a new treatment, and it is not a cure. No one in the study was given a new drug. It is a study of how to name and group tumors, done on tumor samples. This kind of testing is not part of everyday care everywhere yet. More work is needed before it changes how most people are treated.
Source: PubMed, October 29, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.